Cytotoxicity induced by carbon nanotubes in experimental malignant glioma

Despite multiple advances in the diagnosis of brain tumors, there is no effective treatment for glioblastoma. Multiwalled carbon nanotubes (MWCNTs), which were previously used as a diagnostic and drug delivery tool, have now been explored as a possible therapy against neoplasms. However, although th...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of nanomedicine Vol. 12; pp. 6005 - 6026
Main Authors Romano-Feinholz, Samuel, Salazar-Ramiro, Alelí, Muñoz-Sandoval, Emilio, Magaña-Maldonado, Roxana, Hernández Pedro, Norma, Rangel López, Edgar, González Aguilar, Alberto, Sánchez García, Aurora, Sotelo, Julio, Pérez de la Cruz, Verónica, Pineda, Benjamín
Format Journal Article
LanguageEnglish
Published New Zealand Dove Medical Press Limited 01.01.2017
Taylor & Francis Ltd
Dove Medical Press
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Despite multiple advances in the diagnosis of brain tumors, there is no effective treatment for glioblastoma. Multiwalled carbon nanotubes (MWCNTs), which were previously used as a diagnostic and drug delivery tool, have now been explored as a possible therapy against neoplasms. However, although the toxicity profile of nanotubes is dependent on the physicochemical characteristics of specific particles, there are no studies exploring how the effectivity of the carbon nanotubes (CNTs) is affected by different methods of production. In this study, we characterize the structure and biocompatibility of four different types of MWCNTs in rat astrocytes and in RG2 glioma cells as well as the induction of cell lysis and possible additive effect of the combination of MWCNTs with temozolomide. We used undoped MWCNTs (labeled simply as MWCNTs) and nitrogen-doped MWCNTs (labeled as N-MWCNTs). The average diameter of both pristine MWCNTs and pristine N-MWCNTs was ~22 and ~35 nm, respectively. In vitro and in vivo results suggested that these CNTs can be used as adjuvant therapy along with the standard treatment to increase the survival of rats implanted with malignant glioma.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work
ISSN:1178-2013
1176-9114
1178-2013
DOI:10.2147/IJN.S139004